Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Colour-enhanced image of a blood clot. There are many red blood cells and a single white blood cell held together in a meshwork of fibrin. © CC BY-NC Credit Anne Weston, Francis Crick Institute

A study involving Dr Simon Stanworth and Oxford University Hospitals NHS Foundation Trust researchers has recommended that tranexamic acid, routinely used to treat excessive blood loss, should not be used for the treatment of gastrointestinal bleeding.

The results of the HALT-IT trial, a six-year international collaboration, were published in the Lancet on 20 June.

The trial found that tranexamic acid, often used to counteract excessive bleeding during surgery or after major trauma or childbirth, did not reduce deaths from gastrointestinal bleeding but actually increased the risk of deep vein thrombosis or pulmonary embolism. There were also more seizures in those given tranexamic acid.

“It is often assumed that a treatment that works in one bleeding situation will probably work in another, but this trial has shown otherwise. Our results highlight the need for clinical trials that target specific causes of bleeding,” said Dr Stanworth, who is also a Consultant Haematologist at the John Radcliffe Hospital for NHS Blood & Transplant.

“On the basis of these results, we recommend that tranexamic acid should not be used to treat gastrointestinal bleeding, although it has an important role in other patients with major bleeding, such as trauma and post-partum haemorrhage.”

More than 12,000 patients with acute gastrointestinal bleeding took part in this randomised, double-blind trial, half receiving a high-dose 24-hour infusion of tranexamic acid, and the rest a placebo. The trial was conducted 164 hospitals in 15 countries.

The number of patients who died due to bleeding within five days of randomisation was the same, 4%, in both groups, as was the rate of heart attack and stroke (0.7% versus 0.8%).

The level of deep vein thrombosis or pulmonary embolism in the tranexamic acid group was double that in the placebo group (0·8% against 0·4%).

In the UK, the trial was funded by the NIHR’s Health Technology Assessment Programme.

(Text courtesy of OUH)

We want to hear about your news!

Publishing a paper? Just won an award? Get in touch with


Similar stories

Professor Graham Ogg elected Academy of Medical Sciences Fellow

Awards Department General IMD MRC HIU MRC WIMM

Fellows are selected for their exceptional contributions to the advancement of medical science through innovative research discoveries and translating scientific developments into benefits for patients and the wider society.

New funding for early diagnosis research using platelets

Department General MRC MHU MRC WIMM NDCLS OCH Publication Research

Dr Bethan Psaila and her team will investigate the potential of circulating blood platelets for early detection of a range of cancer types.

MRC HIU appoints new Director

Department General MRC HIU MRC WIMM

We are pleased to announce that Professor Alison Simmons has been appointed as the new Director of the MRC Human Immunology Unit.